Viatris (Mylan) has no confirmed US launch yet among the blockbuster drugs on this tracker, holds FDA approval for 1 of them, and has 2 filed or in development. Those brands earned $50.8B in 2025. Of the 70 makers we follow, 17 are lined up to copy more of these drugs.
| Drug | Viatris (Mylan)'s status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| OpsumitGeneric · Johnson & Johnson · US LOE 2026 | FDA-approved 3 Dec 2025 | 2 on sale · 9 approvedof 11 other makers listed | $2.3B |
| Drug | Viatris (Mylan)'s status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| PomalystGeneric · Bristol Myers Squibb · US LOE 2026 | FDA-approved 26 Jan 2022; discontinued | 4 on sale · 6 approvedof 10 other makers listed | $2.7B |
| EliquisGeneric · Bristol Myers Squibb / Pfizer · US LOE 2028 | FDA-approved 23 Dec 2019, not marketed | 0 on sale · 3 approvedof 4 other makers listed, plus unnamed filers | $14.4B |
| Drug | Viatris (Mylan)'s status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| OzempicGeneric · Novo Nordisk · US LOE 2032 | Filed with the FDA; settled, terms confidential | 0 on sale · 1 approvedof 6 other makers listed | ≈$19.3B |
| WegovyGeneric · Novo Nordisk · US LOE 2032 | Filed with the FDA; in litigation, sued Sep 2026. Mylan sued in Sep 2026 to clear a patent running to 2038 | None listedUnnamed filers too | ≈$12.0B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
Each row is a copy Viatris (Mylan) sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Viatris (Mylan)'s full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Viatris (Mylan)'s sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: SEC company tickers.